The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.
Tag Archive for: nipocalimab
Biogen may have found its CEO in Mathai Mammen – former head of research and development in pharmaceuticals at Johnson & Johnson – following the pending departure of current company head Michel Vounatsos.
June is Myasthenia Gravis Awareness month. As with so many rare diseases, the standard of care for myasthenia gravis (MG) doesn’t address the root of the illness and comes with side effects that can be serious. Nipocalimab, which is in Phase III development at Janssen, goes to the cause of the disease.
